Study Published In Endocrinology Reports Potential Of Modigene Technology To Extend Duration Of Protein Drugs
Modigene Inc. (OTC Bulletin Board: MODG) reported that researchers will publish a study in the October edition of the journal Endocrinology showing that erythropoietin (EPO) linked to Modigene’s carboxyl terminal peptide (CTP) technology significantly increased the half-life of standard EPO in animal models.
